DK3793534T3 - Oral tablet til levering af aktive ingredienser til mavetarmkanalen - Google Patents

Oral tablet til levering af aktive ingredienser til mavetarmkanalen Download PDF

Info

Publication number
DK3793534T3
DK3793534T3 DK19729181.8T DK19729181T DK3793534T3 DK 3793534 T3 DK3793534 T3 DK 3793534T3 DK 19729181 T DK19729181 T DK 19729181T DK 3793534 T3 DK3793534 T3 DK 3793534T3
Authority
DK
Denmark
Prior art keywords
delivery
active ingredients
gastrointestinal tract
oral tablet
oral
Prior art date
Application number
DK19729181.8T
Other languages
English (en)
Inventor
Helle Wittorff
Original Assignee
Fertin Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fertin Pharma As filed Critical Fertin Pharma As
Application granted granted Critical
Publication of DK3793534T3 publication Critical patent/DK3793534T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19729181.8T 2018-05-17 2019-05-15 Oral tablet til levering af aktive ingredienser til mavetarmkanalen DK3793534T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/982,593 US20190350858A1 (en) 2018-05-17 2018-05-17 Oral tablet for delivery of active ingredients to the gastrointestinal tract
PCT/DK2019/050159 WO2019219149A1 (en) 2018-05-17 2019-05-15 An oral tablet for delivery of active ingredients to the gastrointestinal tract

Publications (1)

Publication Number Publication Date
DK3793534T3 true DK3793534T3 (da) 2023-05-01

Family

ID=66793737

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19729181.8T DK3793534T3 (da) 2018-05-17 2019-05-15 Oral tablet til levering af aktive ingredienser til mavetarmkanalen

Country Status (8)

Country Link
US (2) US20190350858A1 (da)
EP (1) EP3793534B1 (da)
CN (1) CN112218624A (da)
CA (1) CA3098086C (da)
DK (1) DK3793534T3 (da)
ES (1) ES2943835T3 (da)
PL (1) PL3793534T3 (da)
WO (1) WO2019219149A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096894B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet for induced saliva generation
JP2023525279A (ja) * 2020-05-08 2023-06-15 フェルティン ファルマ アー／エス 活性成分の経口送達用フローパック
CN112220756B (zh) * 2020-10-16 2023-06-13 重庆市义力医药科技有限公司 一种尼古丁颗粒组合物及其制备方法
WO2022130040A1 (en) * 2020-12-19 2022-06-23 Cellix Bio Private Limited A pharmaceutical composition comprising fexofenadine, famotidine and melatonin
WO2022157564A1 (en) * 2021-01-23 2022-07-28 Cellix Bio Private Limited A pharmaceutical composition comprising famotidine, lidocaine and melatonin
WO2023187664A1 (en) * 2022-03-30 2023-10-05 Avaca Pharma Private Limited A pharmaceutical composition for the treatment of immune system mediated diseases

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1080024A (en) 1975-12-24 1980-06-24 Leonard Spooner Confection containing xylitol
US4627977A (en) 1985-09-13 1986-12-09 Colgate-Palmolive Company Anticalculus oral composition
US4820506A (en) 1987-05-01 1989-04-11 Research Foundation, State University Of New York Salivary stimulant
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
GB9100009D0 (en) 1991-01-02 1991-02-20 Cerestar Holding Bv Erythritol compositions
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
TW469135B (en) 1995-10-03 2001-12-21 Chugai Pharmaceutical Co Ltd Chewable tablet
KR20050071718A (ko) 1996-07-12 2005-07-07 다이이찌 세이야꾸 가부시기가이샤 속붕괴성 압축성형물 및 그의 제조법
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
GB9716432D0 (en) 1997-08-05 1997-10-08 Cerestar Holding Bv Tableting of erythritol
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US5874068A (en) 1997-12-08 1999-02-23 Warner-Lambert Company Stabilized antiplaque and antigingivitis oral compositions containing N.sup.α -alkyl-L-arginine alkyl ester salts
EP1047407A4 (en) 1997-12-19 2007-05-02 Smithkline Beecham Corp METHOD FOR PRODUCING A COUTINE TABLET
WO2000025598A1 (en) 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
NZ527113A (en) * 2001-02-08 2005-04-29 Pharmacia Corp Rapid-onset medicament for the treatment of sexual dysfunction
JPWO2002069934A1 (ja) 2001-03-06 2004-07-02 協和醗酵工業株式会社 口腔内速崩壊性製剤
SE0102197D0 (sv) 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
US20030215502A1 (en) 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
AU2003214016A1 (en) 2003-02-04 2004-08-30 Gumlink A/S Compressed chewing gum tablet
US7223072B2 (en) 2004-01-27 2007-05-29 Honeywell International, Inc. Gas turbine engine including airfoils having an improved airfoil film cooling configuration and method therefor
WO2006063189A2 (en) 2004-12-10 2006-06-15 Novartis Ag Multi-layered chewing gum tablet with quick disintegration layer
WO2006112961A2 (en) 2005-03-03 2006-10-26 Takasago International Corp. (Usa) Synergistic salivation components
DE602007005653D1 (de) * 2006-08-04 2010-05-12 Ethypharm Sa Mehrschichtige im mund zerfallende tablette
WO2009007768A1 (en) 2007-07-06 2009-01-15 Gumlink A/S Compressed tablet comprising polyol
US20100255307A1 (en) 2007-07-27 2010-10-07 Cargill Inc. Micronization of polyols
WO2009080023A1 (en) 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising peptide
CN102143692A (zh) 2008-09-04 2011-08-03 卡吉尔公司 赤藓醇的压片
JP5806124B2 (ja) 2009-03-09 2015-11-10 エスピーアイ ファーマ，インコーポレイテッド 高度に圧密可能かつ耐久性のある直接圧縮賦形剤および賦形剤系
US9591852B2 (en) 2009-11-23 2017-03-14 Mcneil-Ppc, Inc. Biofilm disruptive compositions
US8658139B1 (en) 2010-02-27 2014-02-25 Squigle, Inc. Prevention and treatment of oral diseases
JP6521564B2 (ja) 2010-12-22 2019-05-29 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 速崩性の固体被覆剤形
CN104053431A (zh) * 2011-12-22 2014-09-17 费尔廷制药公司 从口香糖中释放烟碱的方法
JP6040218B2 (ja) 2012-02-23 2016-12-07 フロイント産業株式会社 口腔内崩壊錠用直打賦形剤及びその製造方法、並びに口腔内崩壊錠
WO2013171164A1 (en) * 2012-05-14 2013-11-21 EJP Pharmaceutical ApS Compositions and formulations for the treatment of halitosis
AU2014266070A1 (en) 2013-05-17 2015-12-10 Alequident Limited Oral healthcare product
US10357054B2 (en) 2013-10-16 2019-07-23 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
CA2963706C (en) 2014-10-16 2023-10-03 Cargill, Incorporated Process for preparing a directly compressible erythritol & uses thereof
AU2015346374A1 (en) 2014-11-11 2017-04-27 Johnson & Johnson Consumer Inc. Amino acid derivatives and their uses
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
DK3541357T3 (da) * 2016-11-18 2021-05-10 Fertin Pharma As Oral leveringsvehikel
US11351103B2 (en) 2016-11-18 2022-06-07 Johnson & Johnson Consumer Inc. Method of providing oral care benefits
US10543205B2 (en) 2016-11-18 2020-01-28 Fertin Pharma A/S Oral delivery vehicle containing nicotine
CA3044382A1 (en) * 2016-11-18 2018-05-24 Fertin Pharma A/S Method of providing oral care benefits

Also Published As

Publication number Publication date
CN112218624A (zh) 2021-01-12
EP3793534A1 (en) 2021-03-24
WO2019219149A1 (en) 2019-11-21
US20210299052A1 (en) 2021-09-30
US20190350858A1 (en) 2019-11-21
ES2943835T3 (es) 2023-06-16
PL3793534T3 (pl) 2023-06-05
EP3793534B1 (en) 2023-04-05
CA3098086A1 (en) 2019-11-21
US11260030B2 (en) 2022-03-01
CA3098086C (en) 2023-10-17

Similar Documents

Publication Publication Date Title
DK3793534T3 (da) Oral tablet til levering af aktive ingredienser til mavetarmkanalen
DK3506884T3 (da) Sammensætninger til indgivelse af medicin og anvendelser af disse
DK3383363T3 (da) Topiske farmaceutiske formuleringer til behandling af inflammatorisk-relaterede tilstande
DK3068392T5 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
DK3727555T3 (da) Oral delivery of active drug substances
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
DK3634468T3 (da) Fast sammensætning til oral indgivelse
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
DK3491993T3 (da) Kobling til endoskopisk kamera.
DK3551181T3 (da) Behandling omfattende oral eller gastrisk indgivelse af edaravone
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
DK2956149T3 (da) Farmaceutiske sammensætninger til behandling af helicobacter pylori
DK3762009T3 (da) Toxin-afledte indgivelseskonstrukter til oral indgivelse
EP3784214A4 (en) LIQUID ORAL PHARMACEUTICAL DOSAGE FORM
HK1248544A1 (zh) 穩定的口服給藥用藥物組合物
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
DK3307239T3 (da) Formuleringer til indgivelse af RSV- og norovirusantigener i tyndtarmen
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
DK2886108T4 (da) Optimeret farmaceutisk formulering til behandling af inflammatoriske ændringer af øsofagus
EP3346996A4 (en) ORAL PHARMACEUTICAL PHARMACEUTICAL FORM OF BUDESONID
DK3886813T3 (da) Farmaceutiske formuleringer af cyclosporinanaloger
DK3400017T3 (da) Kontinuerlig kompleksering af aktive farmaceutiske ingredienser
EP3826627C0 (de) Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung